Arctic Bioscience - Share capital increase registered

10 Feb 2025 07:53 CET

Reference is made to the stock exchange release published by Arctic Bioscience
3[rd] February 2025 regarding Board approval of share capital increase related
to the exercise of debt conversion rights and corresponding issuance of new
shares in Arctic Bioscience.

The share capital increase has now been registered with the Norwegian Register
of Business Enterprises. As a result, the new share capital of Arctic Bioscience
has increased from NOK 2 536 955,20 to NOK 2 668 934,00, divided into 26 689 340
shares, each having a nominal value of NOK 0,10.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

E-mail: christer@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.

More information:
Access the news on Oslo Bors NewsWeb site